Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toffoli

Showing results (91-100 of 869) with videos related to

Pageof 87
Sort By:
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Colloids and Surfaces. B, Biointerfaces|February 4, 2015
Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albuminA Vicario, V Sergo, G Toffoli, et al.
Pharmacogenomics|November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Cureus|August 21, 2023
Natural History of Untreated Optic Neuritis Associated With Mild COVID-19 InfectionEileen Javidi, Samir Touma, Fares Antaki, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetic optimisation of treatment with oral etoposideGiuseppe Toffoli, Giuseppe Corona, Barbara Basso, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|March 10, 2022
Impact of COVID-19 on pediatric ophthalmology in the epicentre of the Canadian outbreakZoya Chaudhry, Sangeetha Santhakumaran, Jake Schwartz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1996
Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell lineG Toffoli, G Corona, M Gigante, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Pharmacogenetics of irinotecanG Toffoli, E Cecchin, G Corona, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|November 23, 2011
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsGiuseppe Corona, Flavio Rizzolio, Antonio Giordano, et al.
Pageof 87

Showing results (91-100 of 869) with videos related to

Sort By:
Pageof 87
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Colloids and Surfaces. B, Biointerfaces|February 4, 2015
Surface-enhanced Raman spectroscopy of the anti-cancer drug irinotecan in presence of human serum albuminA Vicario, V Sergo, G Toffoli, et al.
Pharmacogenomics|November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Cureus|August 21, 2023
Natural History of Untreated Optic Neuritis Associated With Mild COVID-19 InfectionEileen Javidi, Samir Touma, Fares Antaki, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetic optimisation of treatment with oral etoposideGiuseppe Toffoli, Giuseppe Corona, Barbara Basso, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|March 10, 2022
Impact of COVID-19 on pediatric ophthalmology in the epicentre of the Canadian outbreakZoya Chaudhry, Sangeetha Santhakumaran, Jake Schwartz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1996
Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell lineG Toffoli, G Corona, M Gigante, et al.
Current Medicinal Chemistry. Anti-Cancer Agents|May 29, 2003
Pharmacogenetics of irinotecanG Toffoli, E Cecchin, G Corona, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|November 23, 2011
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsGiuseppe Corona, Flavio Rizzolio, Antonio Giordano, et al.
Pageof 87